1487 related articles for article (PubMed ID: 10788842)
1. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
Sader HS; Tosin I; Sejas L; Miranda E
Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria.
Mohanty S; Singhal R; Sood S; Dhawan B; Das BK; Kapil A
Indian J Med Res; 2005 Nov; 122(5):425-8. PubMed ID: 16456257
[TBL] [Abstract][Full Text] [Related]
3. [In vitro activity of beta-lactam agents and beta-lactamase inhibitors in clinical isolates of Acinetobacter baumannii].
López-Hernández S; Alarcón T; Delgado T; de Las Cuevas MC; López-Brea M
Rev Esp Quimioter; 1999 Jun; 12(2):140-3. PubMed ID: 10562675
[TBL] [Abstract][Full Text] [Related]
4. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
Nomura S; Hanaki H; Nagayama A
J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
[TBL] [Abstract][Full Text] [Related]
5. [Changes of antimicrobial resistance among nonfermenting gram-negative bacilli isolated from intensive care units from 1994 to 2001 in China].
Wang H; Chen MJ;
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):385-90. PubMed ID: 12820914
[TBL] [Abstract][Full Text] [Related]
6. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
[TBL] [Abstract][Full Text] [Related]
7. Implications of beta-lactamase-inhibitor combinations.
Fuchs PC; Barry AL
J Reprod Med; 1990 Mar; 35(3 Suppl):317-21. PubMed ID: 2319514
[TBL] [Abstract][Full Text] [Related]
8. Comparison of antimicrobial resistance of Acinetobacter baumannii clinical isolates from Shanghai and Hong Kong.
Ling TK; Ying CM; Lee CC; Liu ZK
Med Princ Pract; 2005; 14(5):338-41. PubMed ID: 16103700
[TBL] [Abstract][Full Text] [Related]
9. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanic acid and sulbactam combined with ampicillin and piperacillin against beta-lactamase producing anaerobic bacteria.
Nord CE
J Chemother; 1989 Jul; 1(4 Suppl):273-5. PubMed ID: 16312398
[No Abstract] [Full Text] [Related]
10. Sensitivity pattern of gram negative bacilli to three beta-lactam/beta-lactamase inhibitor combinations using the automated API system.
Anuradha K; Sailaja VV; Umabala P; Satheesh T; Lakshmi V
Indian J Med Microbiol; 2007 Jul; 25(3):203-8. PubMed ID: 17901635
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.
Higgins PG; Wisplinghoff H; Stefanik D; Seifert H
Antimicrob Agents Chemother; 2004 May; 48(5):1586-92. PubMed ID: 15105109
[TBL] [Abstract][Full Text] [Related]
12. In vitro activities of piperacillin or cefoperazone alone and in combination with beta-lactamase inhibitors against gram-negative bacilli.
Kuo HY; Wang FD; Yen YF; Lin ML; Liu CY
New Microbiol; 2009 Jan; 32(1):49-55. PubMed ID: 19382669
[TBL] [Abstract][Full Text] [Related]
13. Parenteral beta-lactamase inhibitor combinations for clinical use.
Manzella JP
Am Fam Physician; 1995 May; 51(7):1695-8. PubMed ID: 7754928
[TBL] [Abstract][Full Text] [Related]
14. Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.
Lister PD
Pharmacotherapy; 2000 Sep; 20(9 Pt 2):213S-218S; discussion 224S-228S. PubMed ID: 11001328
[TBL] [Abstract][Full Text] [Related]
15. Development of beta-lactamase inhibitors.
Sutherland R
J Reprod Med; 1990 Mar; 35(3 Suppl):307-12. PubMed ID: 2319512
[TBL] [Abstract][Full Text] [Related]
16. Detection of bacterial strains producing sulbactam- or tazobactam-sensitive beta-lactamases by the use of disks containing the inhibitors alone instead of combining them with antibiotics.
Banic S
APMIS; 2006 Jan; 114(1):3-9. PubMed ID: 16499654
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity against clinically important gram-positive and gram-negative bacteria of sulbactam, alone and in combination with ampicillin, cefotaxime, mezlocillin, and piperacillin.
Schmalreck AF; Wildfeuer A
Arzneimittelforschung; 1990 Oct; 40(10):1145-55. PubMed ID: 2291754
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
Qadri SM; Ueno Y; Cunha BA
Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility survey of piperacillin/tazobactam and some beta-lactam comparators in Italy.
Stefani S; Bonfiglio G; Bianchi C; Zollo A; Nicoletti G
Drugs Exp Clin Res; 1998; 24(2):105-13. PubMed ID: 9675551
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.
Kuck NA; Jacobus NV; Petersen PJ; Weiss WJ; Testa RT
Antimicrob Agents Chemother; 1989 Nov; 33(11):1964-9. PubMed ID: 2558615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
